VHCP Management II LLC decreased its stake in Lipocine Inc. (NASDAQ:LPCN) by 7.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 386,928 shares of the specialty pharmaceutical company’s stock after selling 33,072 shares during the period. Lipocine makes up 0.6% of VHCP Management II LLC’s portfolio, making the stock its 15th largest holding. VHCP Management II LLC owned approximately 2.01% of Lipocine worth $1,555,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Ameriprise Financial Inc. grew its stake in shares of Lipocine by 99.4% in the first quarter. Ameriprise Financial Inc. now owns 131,600 shares of the specialty pharmaceutical company’s stock worth $513,000 after acquiring an additional 65,600 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Lipocine by 7.1% in the first quarter. Bank of New York Mellon Corp now owns 92,979 shares of the specialty pharmaceutical company’s stock worth $362,000 after acquiring an additional 6,191 shares during the last quarter. KCG Holdings Inc. grew its stake in shares of Lipocine by 27.4% in the first quarter. KCG Holdings Inc. now owns 33,537 shares of the specialty pharmaceutical company’s stock worth $131,000 after acquiring an additional 7,219 shares during the last quarter. Federated Investors Inc. PA grew its stake in shares of Lipocine by 9.2% in the second quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock worth $354,000 after acquiring an additional 7,429 shares during the last quarter. Finally, Parametric Portfolio Associates LLC grew its stake in shares of Lipocine by 27.1% in the first quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock worth $229,000 after acquiring an additional 12,518 shares during the last quarter. Institutional investors and hedge funds own 26.39% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Lipocine Inc. (LPCN) Shares Sold by VHCP Management II LLC” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/24/lipocine-inc-lpcn-shares-sold-by-vhcp-management-ii-llc.html.

Several brokerages have recently issued reports on LPCN. Roth Capital set a $38.00 price objective on shares of Lipocine and gave the stock a “buy” rating in a research note on Thursday, August 10th. ValuEngine downgraded shares of Lipocine from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Finally, Canaccord Genuity set a $11.00 price objective on shares of Lipocine and gave the stock a “buy” rating in a research note on Monday, August 7th.

Shares of Lipocine Inc. (NASDAQ:LPCN) traded up 0.24% on Friday, reaching $4.14. The company had a trading volume of 156,490 shares. The company’s 50-day moving average price is $4.12 and its 200-day moving average price is $4.05. The firm’s market capitalization is $85.21 million. Lipocine Inc. has a 52-week low of $3.03 and a 52-week high of $5.90.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Monday, August 7th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). On average, analysts predict that Lipocine Inc. will post ($0.96) earnings per share for the current year.

Lipocine Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Institutional Ownership by Quarter for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.